How can image-based pre-screening change the economics of biomarker-driven programs?
At the Biomarkers, CDx, and Precision Medicine Summit, join our CTO Coleman Stavish and Imagenomix Corp's CEO Travis Wold for H&E to Biomarker: AI Pre-Screening on a Platform That Scales.
They’ll share how AI-derived insights from routine H&E slides can help teams discover biomarkers, prioritize samples for confirmatory testing, and enrich trial populations.
For life sciences, that means opportunities to reduce low-yield testing, identify more potentially eligible patients, and get more value from collected tissue.
After the session, stop by Stand 28 to continue the conversation and see a demo of Concentriq.